Background
Texas Tobacco Barn manufactures and sells vape products in Lubbock, Texas. In September 2020, TTB applied for FDA authorization to sell over 2,200 vape products, including “Barn Brewed Beetle Juice.” FDA denied authorization and warned that the products were “adulterated” and “misbranded” under the Food, Drug, and Cosmetic Act. In May 2023, an FDA inspection found TTB selling the unauthorized e-liquid despite prior warnings.
FDA initiated an administrative proceeding before an HHS administrative law judge seeking a $19,192 civil penalty. FDA presented photographic evidence and inspector testimony showing the unauthorized products for sale in TTB’s retail area. An HHS ALJ found violations proven and imposed the requested penalty. TTB appealed to HHS’s Departmental Appeals Board, which affirmed. TTB petitioned for review in the Fifth Circuit, arguing the administrative proceeding violated its Seventh Amendment right to a jury trial.
The Court’s Holding
The Fifth Circuit GRANTED the petition and VACATED the agency’s penalty decision. The court held that the Seventh Amendment applies to the agency’s enforcement action against TTB. The civil monetary penalty constitutes “the prototypical common law remedy” seeking to punish or deter wrongdoing, not to compensate victims or serve a remedial purpose. The court found the cause of action analogous to common law actions for selling unwholesome goods (trespass-on-the-case) and fraud (the cheat action)—both of which historically involved jury trials and could result in fines.
The court rejected HHS’s reliance on the “public rights exception” to Article III adjudication. Applying SEC v. Jarkesy, the court held that merely invoking “public health” does not strip away Seventh Amendment protections. The exception applies only to matters “historically could have been determined exclusively by the executive and legislative branches”—a showing HHS failed to make. Agency adjudication of FDCA violations lacks the requisite historical pedigree, and Congress cannot “siphon” actions from Article III courts to administrative tribunals merely by assigning them to agencies. The court therefore concluded TTB is entitled to a jury trial in federal district court.
Key Takeaways
- Civil monetary penalties for selling unauthorized FDA-regulated products implicate Seventh Amendment jury-trial rights under Jarkesy’s framework.
- The “public rights exception” to Article III adjudication cannot be expanded beyond its historical limits; “public health” is not an automatic exception.
- The substance and remedy of an enforcement action matter more than where Congress assigns it; the availability of jury trial depends on the action’s historical character, not its statutory novelty.
- FDA enforcement of FDCA violations must occur in federal court with jury trials rather than through administrative adjudication for actions seeking civil penalties.
Why It Matters
This decision significantly constrains FDA’s administrative enforcement authority, particularly for violations involving civil monetary penalties. It requires FDA to pursue FDCA enforcement actions—including those involving tobacco and vape products, food, and drugs—through federal district court litigation with juries rather than through streamlined administrative proceedings. This marks a substantial shift in the enforcement landscape and could substantially increase litigation costs and complexity for FDA while potentially making enforcement slower and less predictable.
The decision’s application of Jarkesy to administrative penalty schemes has broader implications beyond FDA enforcement, signaling that courts will scrutinize whether other regulatory agencies can adjudicate monetary penalties without juries. The ruling also clarifies that even comprehensive, novel regulatory schemes cannot eliminate Seventh Amendment protections when they impose common-law-style remedies.